Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2013 Sep;84(3):600-8.
doi: 10.1038/ki.2013.170. Epub 2013 May 15.

Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS

Manish M Sood  1 , Maria Larkina, Jyothi R Thumma, Francesca Tentori, Brenda W Gillespie, Shunichi Fukuhara, David C Mendelssohn, Kevin Chan, Patricia de Sequera, Paul Komenda, Claudio Rigatto, Bruce M Robinson
Affiliations
Multicenter Study

Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS

Manish M Sood et al. Kidney Int. 2013 Sep.

Abstract

Benefits and risks of antithrombotic agents remain unclear in the hemodialysis population. To help clarify this we determined variation in antithrombotic agent use, rates of major bleeding events, and factors predictive of stroke and bleeding in 48,144 patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS) phases I-IV. Antithrombotic agents including oral anticoagulants (OACs), aspirin (ASA), and anti-platelet agents (APAs) were recorded along with comorbidities at study entry, and clinical events including hospitalization due to bleeding were then collected every 4 months. There was wide variation in OAC (0.3-18%), APA (3-25%), and ASA use (8-36%), and major bleeding rates (0.05-0.22 events/year) among countries. All-cause mortality, cardiovascular mortality, and bleeding events requiring hospitalization were elevated in patients prescribed OACs across adjusted models. The CHADS2 score predicted the risk of stroke in atrial fibrillation patients. Gastrointestinal bleeding in the past 12 months was highly predictive of major bleeding events; for patients with previous gastrointestinal bleeding, the rate of bleeding exceeded the rate of stroke by at least twofold across all categories of CHADS2 score, including patients at high stroke risk. Appropriate risk stratification and a cautious approach should be considered before OAC use in the dialysis population.

PubMed Disclaimer

Conflict of interest statement

All other authors have no conflicts of interest to report.

Figures

Figure 1
Figure 1
Use of antithrombotic agents, by DOPPS phase and country. APA -other than aspirin (clopidogrel, ticlopidine, dipyridamole, pentoxifylline); OAC includes warfarin (85% of total OAC) and a few other products (e.g. fluindione in France); DOPPS study period: phases 1–2 (1998–2004) and 3–4 (2005–10) with N=48,144 patients.
Figure 2
Figure 2
Variation in facility use of antithrombotic agents, by geographic region. N=20,475 patients from DOPPS phases 3 and 4 (2005–2010) in facilities with at least 7 patients with medication use records.
Figure 3
Figure 3
Rates of bleeding events and stroke by country. GI=gastrointestinal, VA=vascular access. N=39,440 patients from DOPPS phases 1,2 and 3. *Other bleeding events include epistaxis, subdural hematoma, evacuation of hematoma, hemoptysis and hematuria. **Stroke includes hospitalization or death due to stroke.
Figure 4
Figure 4
Stroke rate and bleeding rate by CHADS2 score and history of GI bleed. Stroke risk categories are based on CHADS2 categories used commonly in the non-dialysis population: 0=low, 1=moderate, ≥2=high. N=37,657 (N=4,026 atrial fibrillation) patients from DOPPS phases 1, 2 and 3. NOTE: Patient medication usage was classified hierarchically (OAC >APA >ASA for patients taking ≥one medication class. See text for details).
Figure 4
Figure 4
Stroke rate and bleeding rate by CHADS2 score and history of GI bleed. Stroke risk categories are based on CHADS2 categories used commonly in the non-dialysis population: 0=low, 1=moderate, ≥2=high. N=37,657 (N=4,026 atrial fibrillation) patients from DOPPS phases 1, 2 and 3. NOTE: Patient medication usage was classified hierarchically (OAC >APA >ASA for patients taking ≥one medication class. See text for details).
See this image and copyright information in PMC

References

    1. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation. 2001;104:2118–50. - PubMed
    1. Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest. 2008;133:257S–298S. - PubMed
    1. Singer DE, Albers GW, Dalen JE, et al. American College of Chest, Physicians Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest. 2008;133:546S–592S. - PubMed
    1. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91–9. - PubMed
    1. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) Am Heart J. 2006;151:713–9. - PubMed

Publication types